Valneva targets 2022 revenue boost of up to 70% on COVID-19 vaccine

 

French vaccine developer Valneva targets increasing its revenues year-on-year by up to 70% thanks to a boost from its COVID-19 vaccine candidate, it said on Thursday.

The company sees 2022 revenue of between 430 million to 590 million euros ($485.73 million to $666.46 million), including 350 million to 500 million euros of COVID-19 vaccine sales, which are still subject to regulatory approvals and deliveries of their COVID vaccine candidate called VLA2001.

Valneva's 2021 revenue soared 216% year-on-year to 348.1 million euros mainly on COVID-related revenues under a terminated agreement in Britain.

https://www.marketscreener.com/quote/stock/VALNEVA-SE-54466/news/Valneva-targets-2022-revenue-boost-of-up-to-70-on-COVID-19-vaccine-37729547/